search
Back to results

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

Primary Purpose

Inflammatory Bowel Disease

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Lubiprostone
Placebo
Sponsored by
University of South Alabama
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Inflammatory Bowel Disease focused on measuring capsule, endoscopy, prokinetic, lubiprostone, Normal, volunteers

Eligibility Criteria

19 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy volunteers

Exclusion Criteria:

  • Gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea

Sites / Locations

  • USA Pavilion at Infirmary West

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

lubiprostone 24mcg single dose

Sugar pill

Arm Description

lubiprostone 24mcg single dose po prior to capsule endoscopy

Placebo (sugar pill) - matched single dose po prior to capsule endoscopy

Outcomes

Primary Outcome Measures

Complete Small Bowel Transit
Percent of subjects with capsule passage through small bowel

Secondary Outcome Measures

Small Bowel Transit
Small bowel transit time

Full Information

First Posted
September 3, 2008
Last Updated
September 15, 2020
Sponsor
University of South Alabama
Collaborators
Takeda, Sucampo Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00746395
Brief Title
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Official Title
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of South Alabama
Collaborators
Takeda, Sucampo Pharmaceuticals, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.
Detailed Description
Introduction of small bowel capsule endoscopy made available an unique technique for diagnostic evaluation of the gastrointestinal tract. After esophagogastroduodenoscopy and colonoscopy about 5% of bleeding cases remain unexplained and capsule endoscopy provides small bowel yield. Capsule endoscopy has special application for evaluation of inflammation bowel disease and other small bowel conditions. Several adjuncts are used to enhance the examination by improving cleansing preparation or propulsion. Metoclopramide, tegaserod, simethicone, erythromycin, phosphates and polyethylene glycol (PEG) colon cleansing agents have been tried and some show improved visualization or increased propulsion where more capsules reach to colonic cecum while still recording within the limits of its 8 hour battery. Recently, our group had an observational report of our experience showing that either full bowel cleansing preparation or prokinetics such as metoclopramide or tegaserod enhanced visualization and functioning capsule transit to the colon. Lubiprostone is a novel chloride channel activator that increases intestinal fluid secretion and motility. It is FDA approved and indicated for treatment of chronic idiopathic constipation. This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy. The FDA approved 24 mcg constipation dose was chosen because other medications used in similar single dose in our pilot studies appear effective.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammatory Bowel Disease
Keywords
capsule, endoscopy, prokinetic, lubiprostone, Normal, volunteers

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
lubiprostone 24mcg single dose
Arm Type
Active Comparator
Arm Description
lubiprostone 24mcg single dose po prior to capsule endoscopy
Arm Title
Sugar pill
Arm Type
Placebo Comparator
Arm Description
Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
Intervention Type
Drug
Intervention Name(s)
Lubiprostone
Other Intervention Name(s)
Amitiza
Intervention Description
24 mcg oral administration
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar pill
Intervention Description
Oral administration
Primary Outcome Measure Information:
Title
Complete Small Bowel Transit
Description
Percent of subjects with capsule passage through small bowel
Time Frame
8 hours
Secondary Outcome Measure Information:
Title
Small Bowel Transit
Description
Small bowel transit time
Time Frame
Duration of the test - 8 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers Exclusion Criteria: Gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
JAck A DiPalma, MD
Organizational Affiliation
University of South Alabama
Official's Role
Principal Investigator
Facility Information:
Facility Name
USA Pavilion at Infirmary West
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36693
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
19577749
Citation
Hooks SB 3rd, Rutland TJ, Di Palma JA. Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. Gastrointest Endosc. 2009 Nov;70(5):942-6. doi: 10.1016/j.gie.2009.04.045. Epub 2009 Jul 4.
Results Reference
derived

Learn more about this trial

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

We'll reach out to this number within 24 hrs